1:2 Stock Split; Record Date Next Week: Gujarat-Based Penny Stock Under Rs 2 Hits Consecutive 7 Upper Circuits
This penny stock under Rs 2 has been hitting consecutive 7 upper circuits.
On Monday, shares of Murae Organisor Limited (Formerly known as Earum Pharmaceuticals Limited) hit a 5 per cent upper circuit to Rs 1.86 per share from its previous closing of Rs 1.78 per share. The stock’s 52-week high is Rs 2.73 per share and its 52-week low is Rs 1.04 per share. This penny stock under Rs 2 has been hitting consecutive 7 upper circuits.
The Board of Directors approved a 1:2 stock split, subject to shareholder approval, where each equity share with a face value of Rs 2 will be subdivided into two equity shares with a face value of Rs 1 each, to enhance the liquidity of the company's shares and make them more accessible to retail investors; the pre-split subscribed and paid-up share capital of Rs 1,85,89,64,310 divided into 9,29,48,21,55 shares of Rs 2 each will become Rs 1,85,89,64,310 divided into 1,85,89,64,310 shares of Rs 1 each. The Board fixed the record date as Wednesday, June 11, 2025.
The company previously explored acquiring agricultural land in Kutch, Gujarat, with an estimated investment of Rs 200 million to Rs 250 million. The land is intended for cultivating high-quality pomegranates and establishing a distillery facility to enhance operational efficiency and diversify revenue streams. This strategic venture aligns with government initiatives such as the National Horticulture Mission, PMKSY, and the Gujarat Industrial Policy 2020. The final decision is subject to successful due diligence, favourable feasibility reports, and all necessary regulatory approvals.
About the Company
Murae Organisor Ltd., incorporated in 2012, operates within the pharmaceutical industry, focusing on the marketing, trading, and distribution of a diverse range of pharmaceutical formulations. The company markets over 120 products under its brand names, such as HYGNEX+, Erolon, and Calcybar, while outsourcing its manufacturing to third-party facilities. In addition to their branded products, Murae also trades in active pharmaceutical ingredients. Their product portfolio spans various therapeutic categories, including antibiotics, antimalarials, antihistamines, analgesics, dermatology products, neurological drugs, gastrointestinal drugs, and various supplements like calcium and multivitamins. Murae maintains an international presence, exporting to more than 15 countries across North America, CIS, Latin America, Africa, and Southeast Asia, with over 60 international products currently under registration.
According to Quarterly Results, the net sales increased by 59,845 per cent to Rs 515.53 crore and net profit increased by 144 per cent to Rs 2.85 crore in Q4FY25 compared to Q4FY24. In its annual results, the net sales increased by 33,554 per cent to Rs 854.82 crore and net profit increased by 14,940 per cent to Rs 7.52 crore in FY25 compared to FY24
The company has a market cap of Rs 173 crore and its 100 per cent stake is owned by public shareholders. The stock is trading at 0.85 times its book value and the stock is up by 79 per cent from its 52-week low of Rs 1.04 per share.
Disclaimer: The article is for informational purposes only and not investment advice.